Biosimilar Newsletter Archive

  1. 08.10.23 -- Samsung Bioepis Announces Interchangeability Study Results 8/10/2023
    08/10/23 Biosimilar Development Newsletter
  2. 08.03.23 -- FDA Seeks Input On AI Adoption In Drug Development & Manufacture 8/3/2023
    08/03/23 Biosimilar Development Newsletter
  3. 07.27.23 -- 3 Action Items To Mitigate Supply Vulnerabilities 7/27/2023
    07/27/23 Biosimilar Development Newsletter
  4. 07.24.23 -- mAbs On The Express Lane 7/24/2023

    07/24/23 Biosimilar Development Newsletter

  5. 07.20.23 -- Express Scripts Adds 3 Biosimilars To Its Largest Formulary 7/20/2023
    07/20/23 Biosimilar Development Newsletter
  6. 07.19.23 -- Industrializing Drug Delivery - Insights To DeRisk The Transition To Combination Products 7/19/2023

    07/19/23 Biosimilar Development Newsletter

  7. 07.17.23 -- De-Risk Your mRNA Development 7/17/2023

    07/17/23 Biosimilar Development Newsletter

  8. 07.13.23 -- Humira Biosimilars Take The U.S. Market By Storm 7/13/2023
    07/13/23 Biosimilar Development Newsletter
  9. 07.06.23 -- FDA Issues Guidance On Manufacturing Interruptions 7/6/2023
    07/06/23 Biosimilar Development Newsletter
  10. 06.29.23 -- Three Areas To Focus On When Building Security Of Supply 6/29/2023

    06/29/23 Biosimilar Development Newsletter